Summary: The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older...
Summary: A Decentralized, Double-blinded, Randomized, 18 month, Parallel-group, Superiority Study to evaluate the impact of Complement Theory's Live 1:1 Exerci...
Summary: This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer su...
Summary: This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in ...
Summary: The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection.Participants will be asked to:* ...
Summary: This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patie...
Summary: This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 o...
Summary: This pilot randomized double blind controlled crossover study aims to determine the impact of two wrist cooling devices on symptom control of hot flas...
Summary: African-Americans have disparately limited access to optimal cancer care. They have the highest overall cancer death rate and shortest survival time o...
Summary: This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will ...
Summary: Pilot study to determine the feasibility of providing psychosocial and cardiac rehabilitation services to address socioeconomic health disparities and...
Summary: Background:Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples o...
Summary: Background:* It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication...
Summary: NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of...
The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
VISIT
This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.
VISIT
The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.
VISITThe primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide or docetaxel).
VISIT
The LIBERTAS STUDY is researching a way to potentially treat a type of prostate cancer that still responds to hormone therapy. Prostate cancer that spreads to other parts of the body but can still be controlled by interfering with the hormone function of the cancer is called metastatic castration-sensitive prostate cancer (mCSPC).
VISIT
Lorigerlimab is an investigational drug being tested in clinical trials. It is designed to block two checkpoints, telling the immune system cells to wake up and start killing cancer cells. Checkpoint inhibitors, including lorigerlimab, may cause side effects.
VISIT
